Jeffrey Finer, M.D., Ph.D.
Jeff Finer is Interim Chief Executive Officer and Co-Founder of Septerna and brings more than 35 years of research, clinical and business experience. He has focused his career on breakthrough innovations that have included moving several first-in-class drugs into the clinic, developing novel technology platforms which integrate science and engineering, and company creation.
Jeff is a Venture Partner at Third Rock Ventures where he is involved in founding and launching new biotech companies (including Maze Therapeutics and Ambys Medicines where he was the interim Chief Technology Officer at both). Prior to joining Third Rock, Jeff spent several years in R&D leadership positions including Vice President of Research Technology at Theravance Biopharma, Vice President, Discovery at Five Prime Therapeutics, and Director, Drug Discovery Technologies at Cytokinetics. Jeff has current roles on the boards of Strateos, Ambys, and Maze.
Jeff obtained his MD and PhD in Biochemistry from Stanford University School of Medicine, and he holds BS degrees in Chemistry and Biology from the Massachusetts Institute of Technology. He completed residency training in Internal Medicine at Stanford and in Ophthalmology at Massachusetts Eye & Ear Infirmary and Harvard Medical School.